Positive News SentimentPositive NewsNASDAQ:ONCY Oncolytics Biotech (ONCY) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free ONCY Stock Alerts $1.06 +0.03 (+2.91%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.01▼$1.0650-Day Range$0.89▼$1.2552-Week Range$0.88▼$3.39Volume294,181 shsAverage Volume400,928 shsMarket Capitalization$79.95 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Oncolytics Biotech alerts: Email Address Oncolytics Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside371.7% Upside$5.00 Price TargetShort InterestHealthy1.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.32) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.77 out of 5 starsMedical Sector458th out of 938 stocksBiotechnology Industry17th out of 47 stocks 3.5 Analyst's Opinion Consensus RatingOncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Oncolytics Biotech has a forecasted upside of 371.7% from its current price of $1.06.Amount of Analyst CoverageOncolytics Biotech has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.22% of the outstanding shares of Oncolytics Biotech have been sold short.Short Interest Ratio / Days to CoverOncolytics Biotech has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncolytics Biotech has recently decreased by 11.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOncolytics Biotech does not currently pay a dividend.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONCY. Previous Next 3.3 News and Social Media Coverage News SentimentOncolytics Biotech has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Oncolytics Biotech this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for ONCY on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat Follows11 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 6.82% of the stock of Oncolytics Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Oncolytics Biotech are expected to grow in the coming year, from ($0.32) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Oncolytics Biotech Stock (NASDAQ:ONCY)Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More ONCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONCY Stock News HeadlinesMarch 14, 2024 | finanznachrichten.deUSA News Group: Biotech's Role in Addressing the Pancreatic Cancer EmergencyMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment TrialsMarch 29, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 10, 2024 | finance.yahoo.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical TrialsMarch 8, 2024 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsMarch 7, 2024 | prnewswire.comOncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsMarch 5, 2024 | prnewswire.comOncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANMarch 29, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 28, 2024 | prnewswire.comOncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer ConferenceFebruary 15, 2024 | finance.yahoo.comHere's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn SituationFebruary 15, 2024 | baystreet.caOncolytics Biotech IncFebruary 14, 2024 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer CohortFebruary 14, 2024 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer CohortFebruary 14, 2024 | finance.yahoo.comOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer CohortFebruary 14, 2024 | prnewswire.comOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer CohortJanuary 23, 2024 | msn.comOutlook stock rallies on private placement, FDA study agreementJanuary 9, 2024 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of DirectorsJanuary 9, 2024 | finance.yahoo.comOncolytics Biotech® Appoints Patricia S. Andrews to its Board of DirectorsJanuary 4, 2024 | finanznachrichten.deOncolytics Biotech® Inc.: Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024January 4, 2024 | finance.yahoo.comOncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024December 15, 2023 | finance.yahoo.comOncolytics Biotech® and SOLTI Present Positive Translational Data at SABCSDecember 11, 2023 | seekingalpha.comOncolytics Biotech: Numerous Early Readouts, But Dwindling ReservesDecember 8, 2023 | markets.businessinsider.comOptimistic Outlook on Oncolytics Biotech Backed by Promising Pelareorep Trial Data and Strong ValuationNovember 29, 2023 | finance.yahoo.comImproving Survival Rates: Biotech Innovations in Pancreatic Cancer TreatmentNovember 10, 2023 | markets.businessinsider.comPositive Outlook on Oncolytics Biotech: Insights into Clinical Trials and Future PlansNovember 9, 2023 | markets.businessinsider.comOncolytics Announced Positive Interim Results From Phase 1/2 GOBLET Study In Anal CancerSee More Headlines Receive ONCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2023Today3/28/2024Next Earnings (Estimated)5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ONCY CUSIPN/A CIK1129928 Webwww.oncolyticsbiotech.com Phone(403) 670-7377Fax403-283-0858Employees29Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+371.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-105.97% Return on Assets-72.80% Debt Debt-to-Equity RatioN/A Current Ratio9.01 Quick Ratio9.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book3.93Miscellaneous Outstanding Shares75,420,000Free Float75,345,000Market Cap$79.95 million OptionableNot Optionable Beta1.94 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Matthew C. Coffey M.B.A.Ph.D., President, CEO & DirectorMr. Kirk J. Look C.A.CA, Chief Financial OfficerDr. Thomas C. Heineman M.D.Ph.D., Chief Medical OfficerMs. Allison Hagerman P.Eng.P.M.P., Vice President of Product DevelopmentMs. Amy Goodowitz LevinVice President of Clinical OperationsJon PattonDirector of Investor Relations & CommunicationMr. John Mark Lievonen BBAC.M., FCA, LLD, MBA, ConsultantMore ExecutivesKey CompetitorsEnlivex TherapeuticsNASDAQ:ENLVEliem TherapeuticsNASDAQ:ELYMBioLineRxNASDAQ:BLRXAffimedNASDAQ:AFMDLifeVantageNASDAQ:LFVNView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 113,885 shares on 2/15/2024Ownership: 0.153%International Assets Investment Management LLCBought 68,246 shares on 1/24/2024Ownership: 0.362%Advisor Resource CouncilBought 100,000 shares on 1/12/2024Ownership: 0.134%Ausdal Financial Partners Inc.Bought 10,000 shares on 1/11/2024Ownership: 0.041%View All Institutional Transactions ONCY Stock Analysis - Frequently Asked Questions Should I buy or sell Oncolytics Biotech stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONCY shares. View ONCY analyst ratings or view top-rated stocks. What is Oncolytics Biotech's stock price target for 2024? 2 Wall Street research analysts have issued twelve-month price targets for Oncolytics Biotech's shares. Their ONCY share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 371.7% from the stock's current price. View analysts price targets for ONCY or view top-rated stocks among Wall Street analysts. How have ONCY shares performed in 2024? Oncolytics Biotech's stock was trading at $1.35 at the start of the year. Since then, ONCY shares have decreased by 21.5% and is now trading at $1.06. View the best growth stocks for 2024 here. When is Oncolytics Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our ONCY earnings forecast. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (NASDAQ:ONCY) posted its quarterly earnings results on Friday, November, 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.03. During the same quarter in the previous year, the business earned ($0.06) EPS. What is Brad Thompson's approval rating as Oncolytics Biotech's CEO? 2 employees have rated Oncolytics Biotech Chief Executive Officer Brad Thompson on Glassdoor.com. Brad Thompson has an approval rating of 56% among the company's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), KushCo (KSHB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT). Who are Oncolytics Biotech's major shareholders? Oncolytics Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include International Assets Investment Management LLC (0.36%), Citadel Advisors LLC (0.15%), Advisor Resource Council (0.13%) and Ausdal Financial Partners Inc. (0.04%). How do I buy shares of Oncolytics Biotech? Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONCY) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.